Aerie Pharmaceuticals Inc (AERI) Jumps 21.62% on February 18

Equities Staff |

Aerie Pharmaceuticals Inc (AERI) was among the biggest gainers on the Russell 2000 for Thursday February 18 as the stock popped 21.62% to $18.05, representing a gain of $3.209 per share. Some 4.6 million shares traded hands on 22,699 trades, compared with an average daily volume of 397,520 shares out of a total float of 26.36 million. The stock opened at $17.53 and traded with an intraday range of $19.24 to $16.56.

After today's gains, Aerie Pharmaceuticals Inc reached a market cap of $475.86 million. Aerie Pharmaceuticals Inc has had a trading range between $35.89 and $8.84 over the last year, and it had a 50-day SMA of $19.96 and a 200-day SMA of $18.76.

Aerie Pharmaceuticals Inc is a clinical-stage pharmaceutical company engaged in the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.

Aerie Pharmaceuticals Inc is based out of Irvine, CA and has some 40 employees. Its CEO is Vicente Anido.

For a complete fundamental analysis analysis of Aerie Pharmaceuticals Inc, check out Equities.com’s Stock Valuation Analysis report for AERI. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

PixarBio Corp

PixarBio Corp is a specialty pharmaceutical/biotechnology company focused on pre-clinical and commercial development of novel neurological drug delivery systems for post-operative pain.

Private Markets

BioSculpture Technology, Inc.

BioSculpture Technology, Inc. (“BST”) is a commercial-stage medical device manufacturer of liposuction surgical instruments for surgeons. It offers the FDA-cleared Twin Cannula Assisted Liposuction ("TCAL") Airbrush Liposculptor II® controllers, Airbrush®…

Cross Campus

With over 500 members and operating 80,000 square feet by summer 2016, Cross Campus is one of the country’s top ten shared, collaborative office or "coworking" operators in the US.…